Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Apomorphine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 known ✓ | P14416 | 5/20 | 0.91 |
| ▸ | DRD4 known ✓ | P21917 | 1/20 | 0.91 |
| ▸ | DRD3 known ✓ | P35462 | 1/20 | 0.91 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.91 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.91 |
| ▸ | HPGD | P15428 | 6/20 | 0.91 |
| ▸ | MAPT | P10636 | 5/20 | 0.91 |
| ▸ | MAPK1 | P28482 | 5/20 | 0.91 |
| ▸ | HSD17B10 | Q99714 | 5/20 | 0.91 |
| ▸ | TP53 | P04637 | 4/20 | 0.91 |
| ▸ | PKM | P14618 | 4/20 | 0.91 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.91 |
| ▸ | LMNA | P02545 | 4/20 | 0.91 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.91 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.91 |
| ▸ | GAA | P10253 | 3/20 | 0.91 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.91 |
| ▸ | HTR1A | P08908 | 3/20 | 0.91 |
| ▸ | MEN1 | O00255 | 2/20 | 0.91 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.91 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Apomorphine SCHEMBL584927 | 0.97 | KDM4E (0.89) | KDM4EALDH1A1HPGDMAPTMAPK1 | |
| Apomorphine SCHEMBL2256775 | 0.95 | KDM4E (0.89) | KDM4EALDH1A1HPGDMAPTMAPK1 | |
| Apomorphine SCHEMBL17870681 | 0.95 | KDM4E (0.91) | KDM4EALDH1A1HPGDMAPTMAPK1 | |
| (S)Apomorphine SCHEMBL6922802 | 0.95 | KDM4E (1.00) | KDM4EALDH1A1HPGDMAPTMAPK1 | |
| Apomorphine SCHEMBL8541 | 0.95 | KDM4E (1.00) | KDM4EALDH1A1HPGDMAPTMAPK1 | |
| Apomorphine SCHEMBL29414090 | 0.95 | KDM4E (1.00) | KDM4EALDH1A1HPGDMAPTMAPK1 | |
| Apomorphine SCHEMBL1923763 | 0.95 | KDM4E (1.00) | KDM4EALDH1A1HPGDMAPTMAPK1 | |
| (S)Apomorphine SCHEMBL30554804 | 0.95 | KDM4E (1.00) | KDM4EALDH1A1HPGDMAPTMAPK1 | |
| Apomorphine SCHEMBL5605456 | 0.95 | KDM4E (1.00) | KDM4EALDH1A1HPGDMAPTMAPK1 | |
| Apomorphine SCHEMBL29599870 | 0.95 | KDM4E (1.00) | KDM4EALDH1A1HPGDMAPTMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11419769-B2 | Sublingual films | SUNOVION PHARMACEUTICALS INC. (US) | 2022-08-23 | — | — | US | disclosed |
| US-20210322403-A1 | SUBLINGUAL APOMORPHINE | SUNOVION CNS DEVELOPMENT CANADA ULC (CA) | 2021-10-21 | — | — | US | disclosed |
| EP-3735988-A1 | SUBLINGUAL FILMS | Sunovion Pharmaceuticals Inc. (US) | 2020-11-11 | — | — | EP | disclosed |
| EP-2651357-B1 | SUBLINGUAL FILMS | SUNOVION PHARMACEUTICALS INC (US) | 2020-04-01 | — | — | EP | disclosed |
| US-10420763-B2 | Sublingual apomorphine | SUNOVION PHARMACEUTICALS INC. (US) | 2019-09-24 | — | — | US | disclosed |
| EP-3524247-A1 | RAPIDLY DISINTEGRATING FORMULATIONS AND METHODS OF USE | Impax Laboratories, Inc. (US) | 2019-08-14 | — | — | EP | disclosed |
| US-10285953-B2 | Sublingual films | SUNOVION PHARMACEUTICALS INC. (US) | 2019-05-14 | — | — | US | disclosed |
| EP-3434270-A1 | SUBLINGUAL APOMORPHINE | Sunovion Pharmaceuticals Inc. (US) | 2019-01-30 | — | — | EP | disclosed |
| US-20180289699-A1 | SUBLINGUAL APOMORPHINE | ADAGIO PHARMACEUTICALS, LTD. (CA) | 2018-10-11 | — | — | US | disclosed |
| CN-107548388-A | Crystal habit of apomorphine and application thereof | 纽罗德姆有限公司 | 2018-01-05 | — | — | CN | disclosed |
| US-8846074-B2 | Sublingual films | CYNAPSUS THERAPEUTICS, INC. (CA) | 2014-09-30 | — | — | US | disclosed |
| EP-2651357-A1 | SUBLINGUAL FILMS | Cynapsus Therapeutics Inc. (CA) | 2013-10-23 | — | — | EP | disclosed |
| US-20130225626-A1 | SUBLINGUAL FILMS | ARX, LLC (US) | 2013-08-29 | — | — | US | disclosed |
| US-8414922-B2 | Sublingual films | CYNAPSUS THERAPEUTICS, INC. (CA) | 2013-04-09 | — | — | US | disclosed |
| US-20120195955-A1 | SUBLINGUAL FILMS | ARX, LLC (US) | 2012-08-02 | — | — | US | disclosed |
| WO-2012083269-A1 | SUBLINGUAL FILMS | CYNAPSUS THERAPEUTICS, INC. (CA) | 2012-06-21 | — | — | WO | disclosed |
| CN-102480958-A | Sublingual apomorphine | ADAGIO PHARMACEUTICALS LTD | 2012-05-30 | — | — | CN | disclosed |
| EP-2442650-A1 | SUBLINGUAL APOMORPHINE | Adagio Pharmaceuticals Inc. (CA) | 2012-04-25 | — | — | EP | disclosed |
| US-20110111011-A1 | SUBLINGUAL APOMORPHINE | SUNOVION PHARMACEUTICALS INC. | 2011-05-12 | — | — | US | disclosed |
| WO-2010144817-A1 | SUBLINGUAL APOMORPHINE | ADAGIO PHARMACEUTICALS LTD. (CA) | 2010-12-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10420763-B2 | Sublingual apomorphine | PARK7, SNCA, PRNP | DRD2 678/4885DRD4 1055/4885DRD3 1158/4885 |
| US-20120195955-A1 | SUBLINGUAL FILMS | SNCA, COMT, HTR5A | DRD2 12/4885DRD4 28/4885DRD3 29/4885 |
| US-20210322403-A1 | SUBLINGUAL APOMORPHINE | HTR5A, OPRL1, SNCA | DRD2 126/4885DRD4 145/4885DRD3 199/4885 |
| US-10285953-B2 | Sublingual films | SNCA, COMT, HTR5A | DRD2 12/4885DRD4 28/4885DRD3 29/4885 |
| US-20130225626-A1 | SUBLINGUAL FILMS | SNCA, COMT, HTR5A | DRD2 12/4885DRD4 28/4885DRD3 29/4885 |
| US-20180289699-A1 | SUBLINGUAL APOMORPHINE | HTR5A, OPRL1, SNCA | DRD2 126/4885DRD4 145/4885DRD3 199/4885 |
| US-20110111011-A1 | SUBLINGUAL APOMORPHINE | HTR5A, OPRL1, SNCA | DRD2 126/4885DRD4 145/4885DRD3 199/4885 |
| US-11419769-B2 | Sublingual films | SNCA, COMT, HTR5A | DRD2 12/4885DRD4 28/4885DRD3 29/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.